---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-004270"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2024-07-31T23:59:59+00:00"
generated_at: "2026-05-31T14:40:47.309579+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Teva Q2 revenue $4.2B +7%, non-GAAP EPS $0.61, raises full-year 2024 guidance

## Summary
- Revenue $4.2B (+7% USD, +11% local currency); GAAP loss $0.75/share, non-GAAP EPS $0.61.
- Generics grew 16% US, 8% Europe, 22% International; AUSTEDO US revenue $407M (+32%).
- Raised 2024 guidance: revenue $16.0-16.4B, non-GAAP EPS $2.30-2.50, adj. EBITDA $4.6-5.0B.
- Pipeline: duvakitug top-line now Q4 2024; olanzapine LAI positive Phase 3; SIMLANDI launch.
- Free cash flow $324M; $506M tax hit from Israeli Tax Authority settlement.

## SEC filing metadata
- accession: 0001171843-24-004270
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2024-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000117184324004270/0001171843-24-004270-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000117184324004270/f8k_073124.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-004270
- JSON: https://secwatch.observer/filing/0001171843-24-004270.json
- Plain text: https://secwatch.observer/filing/0001171843-24-004270.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.